Experts Discuss Clinical Application of TRK Inhibitors and Tumor Agnostic NTRK Fusion Testing

Experts Discuss Clinical Application of TRK Inhibitors and Tumor Agnostic NTRK Fusion Testing (June 2019)

Sunday, June 2, 2019 in Chicago, Illinois
Dinner -- Sheraton Grand Chicago, 6:30 PM CT
Sheraton Ballroom IV (Ballroom Level)


6:30 – 7:00 PM Dinner and Registration

7:00 – 7:05 PM Welcome and Introduction

7:05 – 8:40 PM Faculty Perspectives on Key Clinical Questions

     Overview and Rationale for Targeting TRK in Solid Tumors

     Clinical Data on TRK Inhibitors

     Implementing NTRK Testing in the Clinic

8:40 – 8:55 PM Panel Discussion and Audience Q&A: Evolving Diagnostic and Treatment Algorithms with NTRK

8:55 – 9:00 PM Conclusions


Todd Bauer, MD

Associate Director, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee

George Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

CCO User, MD

Assistant Professor
Abramson Cancer Center 
Department of Otorhinolaryngology: Head & Neck Surgery 
Department of Medicine, Division of Hematology/Oncology 
Department of Dermatology
Philadelphia, Pennsylvania

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians to plan optimal therapy for their patients with cancer.

Target Audience 
This program is intended for oncologists and other allied healthcare professionals involved in the treatment of cancer.

Learning Objectives

  • Describe the biology of and rationale for targeting cancers containing NTRK fusions
  • Identify patients with cancer who should be tested for NTRK fusions with established and emerging biomarker assays
  • Describe the research data supporting the use of TRK inhibition in a range of cancers harboring NTRK fusions
  • Formulate strategies for using TRK inhibitors in clinical practice once approved
  • Refer adult and pediatric patients to ongoing late-phase clinical trials of TRK inhibitors


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.